InsidersTradesSigma
Track the Neuronetics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Neuronetics, Inc. has published 191 insider filings. Market capitalisation: €249.2m. The latest transaction was disclosed on 19 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MACAN WILLIAM ANDREW. The full history is openly available.
191
Insider Decl.
n/a
Thresholds
€4m
38 ops.
Buy Volume
€6m
75 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Neuronetics, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$6.00.
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,727 of 29,062 companies
19.7
score / 100
Value14
Quality25
FCF yld-9.8%
Earn yld-18%
EV/EBITDA·
ROE-116%
Gross mgn48%
Net mgn-26%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 August 2026
Declarations191 total
149,891 shares@ US$3.0951CommonSEC144:0001959173-26-006219
121,033 shares@ US$3.2080.16% mcap32.9% of flowCommonSEC144:0001959173-26-006183
14,000 shares@ US$3.160.019% mcap1.3% of flowCommon StockSEC:0000921895-26-002204:0
Canonical exit: 12 Nov 2026 (T+90)
35,000 shares@ US$1.780.051% mcap1.9% of flowCommon StockSEC:0000921895-26-001811:0
Canonical exit: 12 Oct 2026 (T+90)
2,934 sharesCommon StockSEC:0001193125-26-274343:0
34,932 sharesCommon StockSEC:0001193125-26-274343:1
4,634 sharesCommon StockSEC:0001193125-26-274343:2
42,164 shares@ US$1.28890.044% mcap2.5% of flowCommonSEC144:0001959173-26-004449
30,000 shares0Common StockSEC:0002044406-26-000002:0
36,250 shares0Common StockSEC:0001218713-26-000002:0
30,000 shares0Common StockSEC:0001238659-26-000002:0
30,000 shares0Common StockSEC:0002004858-26-000002:0
100,000 shares@ US$1.580.14% mcap51.0% of flowCommon StockSEC:0000921895-26-001056:0
Canonical exit: 19 Jul 2026 (T+90)
100,000 shares@ US$1.510.14% mcap49.0% of flowCommon StockSEC:0000921895-26-001056:1
Canonical exit: 20 Jul 2026 (T+90)
337,312 shares0Common StockSEC:0001193125-26-138142:0
337,312 shares0Common StockSEC:0001193125-26-138142:1
385,442 shares@ US$1.2529.6% of flowCommon StockSEC:0000921895-26-000835:0
Canonical exit: 28 Jun 2026 (T+90)
500,000 shares@ US$1.3541.2% of flowCommon StockSEC:0000921895-26-000822:0
Canonical exit: 25 Jun 2026 (T+90)
125,000 shares@ US$1.4010.6% of flowCommon StockSEC:0000921895-26-000813:0
Canonical exit: 23 Jun 2026 (T+90)
16,431 shares@ US$1.34100.0% of flowCommon StockSEC:0001193125-26-122298:0
16,005 shares@ US$1.342.9% of flowCommon StockSEC:0001193125-26-122290:0
46,289 shares@ US$1.343.1% of flowCommon StockSEC:0001193125-26-122295:0
1,500,000 shares0Common StockSEC:0001563602-26-000006:0
169,472 shares@ US$1.418.8% of flowCommon StockSEC:0001193805-26-000308:0
Canonical exit: 18 Jun 2026 (T+90)
25 of 191 declarations
关于 Neuronetics, Inc.
Neuronetics, Inc.（股票代码：STIM）是一家在美国纳斯达克市场上市的美国医疗技术公司。该公司专注于非侵入性神经健康疗法的设计、开发、商业化和支持，主要侧重于精神健康障碍。Neuronetics总部位于宾夕法尼亚州马尔文，是一家商业化阶段的垂直整合医疗保健企业，结合了设备销售、临床服务以及与治疗交付和患者可及性相关的经常性收入流。（[ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai)) Neuronetics成立于2000年代后期，其业务围绕其旗舰产品NeuroStar Advanced Therapy构建，这是一种用于办公室护理环境的经颅磁刺激（TMS）系统。NeuroStar已获得FDA批准，用于治疗当前发作中对先前抗抑郁药物未获得满意改善的重度抑郁症成年患者。该监管批准具有重要的战略意义，因为它支持医生采纳、支付方参与以及在仍处于发展阶段的治疗类别中更广泛的临床接受度。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1227636/000110465926029004/stim-20251231x10k.htm?utm_source=openai)) 该公司的运营模式围绕三个主要经济驱动因素：NeuroStar系统的销售、服务和诊所相关收入，以及与系统利用和支持相关的其他收入。这种混合模式使Neuronetics既能参与资本设备的前期销售，又能参与治疗交付的持续经济效益。公司近期披露的信息表明，其诊所业务一直是重要的增长引擎，管理层还强调了运营现金流的改善以及美国市场商业节奏的加强。（[ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai)) 从竞争角度来看，Neuronetics是抑郁症TMS领域知名品牌之一，其市场渗透率相对于可及患者群体的规模而言仍然不足。公司一直在通过旨在扩大患者可及性和提供者覆盖范围的合作伙伴关系来加强其商业足迹。一个显著的例子是其与Elite DNA Behavioral Health（佛罗里达州最大、增长最快的行为健康网络之一）为期三年的独家合作，旨在使NeuroStar成为该网络所有站点的唯一TMS设备。Neuronetics还通过收购Greenbrook TMS扩大了规模，这扩大了其诊所足迹并增加了经常性治疗收入的敞口。（[ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-announces-three-year-exclusive-partnership-elite-dna/?utm_source=openai)) 从地理上看，Neuronetics仍然高度专注于美国，美国是其核心商业市场和主要收入来源。公司最新的更新强调了持续的国内执行：在2026年第一季度，Neuronetics报告了收入增长、更高的美国诊所收入、更多在美国发货的NeuroStar系统，以及与去年同期相比改善的运营现金流出。对于投资者而言，该股票代表了纳斯达克市场上一个专业的医疗保健公司，面临着报销趋势、临床采纳以及商业化阶段医疗技术公司典型的执行风险。（[ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai))
